The Series A round will fund the continued development of the company platform for hard-to-drug targets.
"We are advancing this technology and its application to the hit discovery, hit-to-lead and lead optimization processes of small molecule drug discovery."
The funding round was backed by Jefferies, Antara Capital, Sony Innovation Fund, and FM Capital.
"Over the past 9 years, we have developed a unique software platform that addresses the core challenges of electric vehicle fleets. From predictive maintenance and repair automation to fine-grain location and curb management, our platform is rich with advanced capabilities that enable safer and more reliable transportation solutions,"